India faces an 'epidemic' of heart disease

29 September 2017
india_big-1

Cardiovascular diseases (CVDs) are expected to be the fastest growing chronic illnesses between 2007 and 2017, growing at 9.5% annually, and accounting for the second largest number of non-communicable diseases (NCDs) patients after mental illnesses in India, according to an ASSOCHAM-Deloitte joint study on the occasion of ‘World Heart day,’ posted on the Associated Chambers of Commerce & Industry of India (ASSOCHAM) website.

A day ahead of the World Heart day (September 29), a joint study prepared by ASSOCHAM and Deloitte on ‘Cardiovascular diseases in India’ reveals that CVDs accounted for around one-fourth of all deaths in India in 2008. A more worrying fact is that the incidences of CVDs have gone up significantly for people between the ages 25 and 69 to 24.8%, which means we are losing more productive people to these diseases.

Between 2007 and 2017, India is projected to cumulatively lose $236.6 billion because of heart disease, stroke, and diabetes, shaving 1% off the GDP. In 2000, in the age group of 35 to 64, India lost 9.2 million years of productive life (PYLLs), almost six times the figure for USA, noted the study.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical